Between 2022 and 2025, several ultra-high-cost, one-time therapies were approved in the United States, offering potentially curative options for conditions such as spinal muscular atrophy, hemophilia, and sickle cell disease. Despite their clinical value, upfr... ...

请注册登录后继续浏览